April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Inhibition Of Choroidal Neovascularization By Targeting To Membrane Protein Cd9
Author Affiliations & Notes
  • Hiroto Terasaki
    Ophthalmology,
    Kagoshima Univ Sch of Medicine, Kagoshima-shi, Japan
  • Taro Kamisasanuki
    Ophthalmology,
    Kagoshima Univ Sch of Medicine, Kagoshima-shi, Japan
  • Ken-ichiro Kosai
    Gene Therapy and Regenerative Medicine,
    Kagoshima Univ Sch of Medicine, Kagoshima-shi, Japan
  • Taiji Sakamoto
    Ophthalmology,
    Kagoshima Univ Sch of Medicine, Kagoshima-shi, Japan
  • Footnotes
    Commercial Relationships  Hiroto Terasaki, None; Taro Kamisasanuki, None; Ken-ichiro Kosai, None; Taiji Sakamoto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 975. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroto Terasaki, Taro Kamisasanuki, Ken-ichiro Kosai, Taiji Sakamoto; Inhibition Of Choroidal Neovascularization By Targeting To Membrane Protein Cd9. Invest. Ophthalmol. Vis. Sci. 2011;52(14):975.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We previously reported that corneal neovascularization was inhibited by blocking membrane protein CD9, indicating that CD9 plays a pivotal role ocular angiogenesis (ARVO 2010). In the present study, we examined the effect of blocking CD9 on choroidal neovascularization (CNV) in a mouse laser-model and further investigated its therapeutic potential for exudative age-related macular degeneration.

Methods: : Laser-induced CNV model was produced in C57BL/6 mouse (n=20). CD9 was blocked by inhibitors of either siRNA-CD9 or mouse monoclonal antibody against CD9 (SantaCruz). Each inhibitor was injected into the vitreous on the same day and 7 days after laser shot. On day 14, mice were sacrificed and perfused with FITC-dextran. The size of each CNV was measured by image analyzing system (ImageJ software). Random siRNA was used as a control of siRNA-CD9 and Phosphate buffered saline(PBS) was used as a control of anti-CD9 antibody.

Results: : The size of CNV was significantly smaller in siRNA-CD9-treated eyes than controls: the average reduced size was 0.28% vs random siRNA or 0.38% vs PBS). It was also smaller in anti-CD9-treated CNV than in controls (0.013±0.009 mm2 anti-CD9 antibody vs 0.023±0.01 mm2 control, P=0.022, student t test).

Conclusions: : Blocking of CD9 resulted in inhibition of laser-induced CNV in mouse. CD9 can be a promising target molecule for the treatment of exudative age-related macular degeneration.

Keywords: gene transfer/gene therapy • age-related macular degeneration • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×